The JAMA Psychiatry publication adds strong external validation to GH001's efficacy, increasing confidence in the upcoming Phase 3 program. Traders should monitor for Phase 3 trial initiation, regulatory feedback, and potential partnership announcements, which could act as near-term catalysts.
Price Chart
Executive Summary
GH Research PLC announced the publication of Phase 2b trial results for its lead candidate GH001 in treatment-resistant depression (TRD) in JAMA Psychiatry, along with a secondary analysis showing efficacy independent of prior antidepressant treatment failures. These peer-reviewed findings support the drug's potential as a practice-changing therapy and de-risk the upcoming Phase 3 program.
Key Facts
- Phase 2b results for GH001 in TRD published in JAMA Psychiatry, a top-tier peer-reviewed journal.
- GH001 achieved a statistically significant MADRS reduction of −15.5 points vs placebo by Day 8 (P<0.0001).
- New analysis shows remission rates remained high (53.9%–63.6% on Day 8, 61.5%–85.7% at Month 6) regardless of prior antidepressant failures, breaking the STAR*D trend.
- No correlation between prior treatment failures and MADRS improvement (r=−0.13; P=0.44 at Day 8).
- Data supports advancement into global pivotal Phase 3 trials.
Financial Impact
Significant de-risking of clinical pipeline; increases probability of regulatory success and partnership potential. Market cap currently $831M reflects early-stage valuation with substantial upside if Phase 3 succeeds.
Risk Factors
- Phase 2b results may not replicate in larger Phase 3 trials.
- Regulatory pathways for TRD treatments remain complex and uncertain.
- Competition from other rapid-acting antidepressants (e.g., esketamine, psychedelics in development).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262385 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 6-K | $21.11 $18.15 | ▼ −14.02% | ▼ −12.05% | $19.18 (−9.14%) |
Sep 11, 2026 6w ago | 6-K | $27.20 $28.26 | ▲ +3.90% | ▲ +4.12% | $19.18 (−29.49%) |
Aug 6, 2026 11w ago | 6-K | $30.64 $28.19 | ▼ −8.00% | ▼ −9.21% | $19.18 (−37.40%) |
May 14, 2026 23w ago | 424B5 | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
May 14, 2026 23w ago | 6-K | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 14, 2026 23w ago | Press Release | $22.21 $21.77 | ▼ −1.98% | ▼ −1.26% | $19.18 (−13.64%) |
May 13, 2026 23w ago | 6-K | $22.21 $21.77 | ▲ +1.98% | ▲ +1.26% | $19.18 (+13.64%) |
Apr 29, 2026 25w ago | 424B5 | $19.16 $21.28 | ▼ −11.06% | ▼ −7.95% | $19.18 (−0.10%) |
Apr 1, 2026 29w ago | 3 | $14.57 $15.72 | ▲ +7.89% | ▲ +4.27% | $19.18 (+31.64%) |
Mar 25, 2026 30w ago | Press Release | $13.65 $14.72 | ▲ +7.84% | ▲ +8.08% | $19.18 (+40.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers